Compounds > dihydroxyphenylalanine
Page last updated: 2024-10-18

dihydroxyphenylalanine and Paraganglioma

dihydroxyphenylalanine has been researched along with Paraganglioma in 33 studies

Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.

Paraganglioma: A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992)

Research Excerpts

ExcerptRelevanceReference
"(18)F-fluorodihydroxyphenylalanine (FDOPA) is a powerful tool for the diagnosis and detection of neuroendocrine tumors when planning and monitoring surgical and oncologic therapies."8.9018F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. ( Forsback, S; Kauhanen, S; Kemppainen, J; Minn, H; Seppänen, M, 2014)
"The aim of this study was to systematically review and conduct a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) in patients with paraganglioma (PG)."8.88Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. ( Castaldi, P; Cocciolillo, F; de Waure, C; Di Nardo, F; Giordano, A; Gualano, MR; Rufini, V; Treglia, G, 2012)
"To evaluate (18)F-fluorodihydroxyphenylalanine-positron emission tomography/ contrast-enhanced computed tomography ((18)F-DOPA PET/CT) for the detection of paragangliomas (PARA) without any patient selection, such as genetic predisposition for the development of these tumors, history of metastatic PARA or hormonal status."7.83Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma. ( Dudczak, R; El-Rabadi, K; Hacker, M; Karanikas, G; Mayerhofer, M; Mitterhauser, M; Nakuz, T; Scherer, T; Weber, M, 2016)
"Pheochromocytomas (PHEOs) and paragangliomas (PGLs) may be better detected by (18)F-fluorodihydroxyphenylalanine-positron emission tomography (FDOPA-PET) than (123)I-metaiodobenzyl-guanidine (123-I-MIBG) scintigraphy."7.766-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transpo ( Anlauf, M; Bartenstein, P; Fottner, C; Helisch, A; Klöppel, G; Kreft, A; Lackner, KJ; Musholt, TJ; Rossmann, H; Schadmand-Fischer, S; Schreckenberger, M; Weber, MM, 2010)
"(18)F-fluorodihydroxyphenylalanine (FDOPA) is a powerful tool for the diagnosis and detection of neuroendocrine tumors when planning and monitoring surgical and oncologic therapies."4.9018F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. ( Forsback, S; Kauhanen, S; Kemppainen, J; Minn, H; Seppänen, M, 2014)
"The aim of this study was to systematically review and conduct a meta-analysis of published data about the diagnostic performance of (18)F-dihydroxyphenylalanine (DOPA) positron emission tomography (PET) in patients with paraganglioma (PG)."4.88Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis. ( Castaldi, P; Cocciolillo, F; de Waure, C; Di Nardo, F; Giordano, A; Gualano, MR; Rufini, V; Treglia, G, 2012)
"To evaluate (18)F-fluorodihydroxyphenylalanine-positron emission tomography/ contrast-enhanced computed tomography ((18)F-DOPA PET/CT) for the detection of paragangliomas (PARA) without any patient selection, such as genetic predisposition for the development of these tumors, history of metastatic PARA or hormonal status."3.83Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma. ( Dudczak, R; El-Rabadi, K; Hacker, M; Karanikas, G; Mayerhofer, M; Mitterhauser, M; Nakuz, T; Scherer, T; Weber, M, 2016)
"To evaluate the clinical value of (18) F-fluorodihydroxyphenylalanine ((18) F-FDOPA) PET in relation to tumour localization and the patient's genetic status in a large series of pheochromocytoma/paraganglioma (PHEO/PGL) patients and to discuss in detail false-negative results."3.79Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. ( Barlier, A; Blanchet, EM; Chen, CC; Deveze, A; Fakhry, N; Gabriel, S; Morange, I; Pacak, K; Sebag, F; Taïeb, D, 2013)
"To define the appropriate scan time for fluorine-18-labeled dihydroxyphenylalanine (F-18 DOPA) PET in oncological imaging of pheochromocytomas and paragangliomas."3.78Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas? ( Boedeker, CC; Brink, I; Hentschel, M; Neumann, HP; Rottenburger, C, 2012)
"Pheochromocytomas (PHEOs) and paragangliomas (PGLs) may be better detected by (18)F-fluorodihydroxyphenylalanine-positron emission tomography (FDOPA-PET) than (123)I-metaiodobenzyl-guanidine (123-I-MIBG) scintigraphy."3.766-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transpo ( Anlauf, M; Bartenstein, P; Fottner, C; Helisch, A; Klöppel, G; Kreft, A; Lackner, KJ; Musholt, TJ; Rossmann, H; Schadmand-Fischer, S; Schreckenberger, M; Weber, MM, 2010)
"Besides (123)I-metaiodobenzylguanidine (MIBG), positron emission tomography (PET) agents are available for the localization of paraganglioma (PGL), including (18)F-3,4-dihydroxyphenylalanine (DOPA), (18)F-fluoro-2-deoxy-D-glucose ((18)F-FDG), and (18)F-fluorodopamine ((18)F-FDA)."3.75Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. ( Adams, KT; Carrasquillo, JA; Chen, CC; Eisenhofer, G; Havekes, B; Ling, A; Martiniova, L; Pacak, K; Timmers, HJ; Whatley, M, 2009)
"Paragangliomas are tumours that arise within the sympathetic nervous system originating from the neural crest."2.43Imaging of pheochromocytoma and paraganglioma. ( Bley, TA; Brink, I; Hoegerle, S; Klisch, J, 2005)
"F-FDOPA PET/CT disconfirmed this recurrence but revealed 2 FDOPA-avid left inguinal lymph nodes, confirmed on a subsequent F-FDG PET/CT."1.56Incidental Metastatic Melanoma Identified on 18F-FDOPA PET/CT With Confirmation by Histology. ( Aouidad, I; Jublanc, C; Montravers, F; Talbot, JN; Zhang-Yin, J, 2020)
"Paragangliomas and pheochromocytomas are genetically heterogeneous diseases."1.38Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET. ( Benz, MR; Campbell, D; Dumont, RA; Mix, M; Neumann, HP; Rischke, HC; Rössler, J; Seufert, J; Weber, WA; Wiech, T; Wild, D, 2012)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (18.18)29.6817
2010's24 (72.73)24.3611
2020's3 (9.09)2.80

Authors

AuthorsStudies
Goujon, A1
Pop, G1
Hissier, J1
Moreau, B1
Palard-Novello, X1
Zhang-Yin, J1
Jublanc, C1
Aouidad, I1
Montravers, F1
Talbot, JN1
Araghi, ZJ1
Ranjbar, S1
Paar, M1
Pirich, C1
Beheshti, M1
Berends, AMA1
Kerstens, MN2
Bolt, JW1
Links, TP2
Korpershoek, E1
de Krijger, RR1
Walenkamp, AME1
Noordzij, W1
van Etten, B1
Kats-Ugurlu, G1
Brouwers, AH2
van der Horst-Schrivers, ANA1
Leroy Freschini, B1
Addeo, P1
Averous, G1
Goichot, B2
Bachellier, P1
Imperiale, A2
Calabrò, D1
Allegri, V1
Fanti, S2
Ambrosini, V1
Blanchet, EM3
Martucci, V2
Millo, C2
Chen, CC5
Herscovitch, P2
Pacak, K9
Maass-Moreno, R1
Bluemke, DA1
Taïeb, D6
Timmers, HJ2
Shulkin, BL1
Minn, H1
Kemppainen, J1
Kauhanen, S1
Forsback, S1
Seppänen, M1
Santhanam, P1
Treglia, G3
Ruberto, T1
Giovanella, L1
Shamim, SA1
Kumar, A1
Kumar, R1
Janssen, I1
Patronas, NJ1
Millo, CM1
Adams, KT4
Nambuba, J1
Sadowski, SM1
Fojo, AT1
Buchmann, I1
Kebebew, E1
Archier, A1
Varoquaux, A1
Garrigue, P1
Montava, M1
Guerin, C1
Gabriel, S2
Beschmout, E1
Morange, I2
Fakhry, N2
Castinetti, F1
Sebag, F2
Barlier, A2
Loundou, A1
Guillet, B1
Knie, B1
Plotkin, M1
Zschieschang, P1
Prasad, V1
Moskopp, D1
El-Rabadi, K1
Weber, M1
Mayerhofer, M1
Nakuz, T1
Scherer, T1
Mitterhauser, M1
Dudczak, R1
Hacker, M1
Karanikas, G1
Fiebrich, HB1
Pijl, ME1
Kema, IP1
de Jong, JR1
Jager, PL1
Elsinga, PH1
Dierckx, RA1
van der Wal, JE1
Sluiter, WJ1
de Vries, EG1
Carrasquillo, JA1
Whatley, M1
Ling, A2
Havekes, B1
Eisenhofer, G2
Martiniova, L1
Chew, SL1
Fottner, C1
Helisch, A1
Anlauf, M1
Rossmann, H1
Musholt, TJ1
Kreft, A1
Schadmand-Fischer, S1
Bartenstein, P1
Lackner, KJ1
Klöppel, G1
Schreckenberger, M1
Weber, MM1
Rufini, V2
Castaldi, P2
Perotti, G1
Calcagni, ML1
Corsello, SM1
Galli, G1
Giordano, A2
Levine, DS1
Metzger, DL1
Nadel, HR1
Oviedo, A1
Adam, MJ1
Skarsgard, E1
King, KS1
Alexopoulos, DK1
Whatley, MA1
Reynolds, JC1
Patronas, N1
Xekouki, P1
Lando, H1
Stratakis, CA1
Hentschel, M1
Rottenburger, C1
Boedeker, CC1
Neumann, HP4
Brink, I4
Cocciolillo, F1
de Waure, C1
Di Nardo, F1
Gualano, MR1
Rischke, HC1
Benz, MR1
Wild, D1
Mix, M1
Dumont, RA1
Campbell, D1
Seufert, J1
Wiech, T1
Rössler, J1
Weber, WA1
Taquet, MC1
Rust, E1
Hubele, F1
Veillon, F1
Deveze, A1
Hoegerle, S2
Ghanem, N1
Altehoefer, C1
Schipper, J1
Moser, E1
Goldstein, DS1
Sullivan, P1
Csako, G1
Brouwers, FM1
Lai, EW1
Klisch, J1
Bley, TA1
Schaefer, O1
Walz, M1

Reviews

5 reviews available for dihydroxyphenylalanine and Paraganglioma

ArticleYear
18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.
    PET clinics, 2014, Volume: 9, Issue:1

    Topics: Adrenal Gland Neoplasms; Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Humans; Intestinal Neopl

2014
Role of (18) F-FDOPA PET/CT imaging in endocrinology.
    Clinical endocrinology, 2014, Volume: 81, Issue:6

    Topics: Adrenal Gland Neoplasms; Carbidopa; Carcinoid Tumor; Carcinoma, Neuroendocrine; Dihydroxyphenylalani

2014
PET/Computed Tomography in Neuroendocrine Tumor: Value to Patient Management and Survival Outcomes.
    PET clinics, 2015, Volume: 10, Issue:3

    Topics: Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Gallium Radioisotopes; Gast

2015
Diagnostic performance of 18F-dihydroxyphenylalanine positron emission tomography in patients with paraganglioma: a meta-analysis.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:7

    Topics: Dihydroxyphenylalanine; Humans; Multimodal Imaging; Paraganglioma; Positron-Emission Tomography; Rad

2012
Imaging of pheochromocytoma and paraganglioma.
    Familial cancer, 2005, Volume: 4, Issue:1

    Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Huma

2005

Trials

3 trials available for dihydroxyphenylalanine and Paraganglioma

ArticleYear
Integrated whole-body PET/MRI with 18F-FDG, 18F-FDOPA, and 18F-FDA in paragangliomas in comparison with PET/CT: NIH first clinical experience with a single-injection, dual-modality imaging protocol.
    Clinical nuclear medicine, 2014, Volume: 39, Issue:3

    Topics: Adult; Dihydroxyphenylalanine; Dopamine; Female; Fluorodeoxyglucose F18; Humans; Injections; Magneti

2014
Prospective comparison of (68)Ga-DOTATATE and (18)F-FDOPA PET/CT in patients with various pheochromocytomas and paragangliomas with emphasis on sporadic cases.
    European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:7

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; False Positive Reac

2016
18F-DOPA positron emission tomography for the detection of glomus tumours.
    European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:5

    Topics: Adult; Aged; Carotid Body Tumor; Dihydroxyphenylalanine; Female; Glomus Tumor; Humans; Male; Middle

2003

Other Studies

25 other studies available for dihydroxyphenylalanine and Paraganglioma

ArticleYear
18 F-FDOPA PET/CT of Paraganglioma in the Spermatic Cord.
    Clinical nuclear medicine, 2023, May-01, Volume: 48, Issue:5

    Topics: Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Humans; Male; Middle Aged; Paraganglioma; Positron

2023
Incidental Metastatic Melanoma Identified on 18F-FDOPA PET/CT With Confirmation by Histology.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:10

    Topics: Dihydroxyphenylalanine; Female; Humans; Incidental Findings; Melanoma; Middle Aged; Neoplasm Staging

2020
Accurate detection of intracranial extension of jugulotympanic paraganglioma by [
    European journal of nuclear medicine and molecular imaging, 2021, Volume: 49, Issue:1

    Topics: Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Paraganglioma; Positron Emission Tomogra

2021
False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
    European journal of endocrinology, 2018, Volume: 179, Issue:2

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; False Positive Reactions; Female; Huma

2018
18F-FDOPA PET/CT of Nonfunctioning Paraganglioma of the Gastroepiploic Pedicle.
    Clinical nuclear medicine, 2018, Volume: 43, Issue:9

    Topics: Diagnosis, Differential; Dihydroxyphenylalanine; Female; Gastrointestinal Neoplasms; Humans; Mesente

2018
    European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:6

    Topics: Abdominal Neoplasms; Dihydroxyphenylalanine; Head and Neck Neoplasms; Humans; Hypertension; Image Pr

2019
Multitracer PET imaging of bone metastases from paraganglioma: peripheral halo of uptake on 18F-FLT PET mismatching with central uptake of 18F-FDOPA, 18F-fluorodopamine, and 18F-FDG.
    European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:12

    Topics: Adrenal Gland Neoplasms; Aged; Biological Transport; Bone Neoplasms; Dideoxynucleosides; Dihydroxyph

2013
Renaissance of (18)F-FDG positron emission tomography in the imaging of pheochromocytoma/paraganglioma.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:7

    Topics: Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; History, 20th Century; Hist

2014
Trimodal (18)F-DOPA PET/CT/MR fusion imaging for optimal restaging of head and neck paragangliomas in a SDHD mutation carrier.
    Endocrine, 2016, Volume: 52, Issue:2

    Topics: Adult; Dihydroxyphenylalanine; Female; Head and Neck Neoplasms; Humans; Magnetic Resonance Imaging;

2016
68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:2

    Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans

2016
A family with pheochromocytoma-paraganglioma inherited tumour syndrome. Serial 18F-DOPA PET/CT investigations.
    Nuklearmedizin. Nuclear medicine, 2016, Volume: 55, Issue:1

    Topics: Adult; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neoplastic Syndromes, Hereditary;

2016
Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma.
    Anticancer research, 2016, Volume: 36, Issue:8

    Topics: Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; False Negative Reactions; Female; Huma

2016
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine exces
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:10

    Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adrenal Glands; Adult; Aged; Biomarkers;

2009
Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:12

    Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; Dop

2009
Diagnosis: imaging of pheochromocytomas and paragangliomas.
    Nature reviews. Endocrinology, 2010, Volume: 6, Issue:4

    Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Contrast Media; Diagnostic Imaging; Dihydroxyphenyla

2010
6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transpo
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6

    Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Biomarkers; Data Interpreta

2010
Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
    Nuclear medicine communications, 2011, Volume: 32, Issue:7

    Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; Female; Humans;

2011
Novel use of F-DOPA PET/CT imaging in a child with paraganglioma/pheochromocytoma syndrome.
    Pediatric radiology, 2011, Volume: 41, Issue:10

    Topics: Adolescent; Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Female; Humans; Kidney Neoplasms; Multi

2011
Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:9

    Topics: 3-Iodobenzylguanidine; Adult; Brain Mapping; Dihydroxyphenylalanine; Dopamine; Female; Fluorodeoxygl

2011
Is there an optimal scan time for 6-[F-18]fluoro-L-DOPA PET in pheochromocytomas and paragangliomas?
    Clinical nuclear medicine, 2012, Volume: 37, Issue:2

    Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female;

2012
Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:9

    Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Aged, 80 and over; Biological Transport; Child; Di

2012
Head-to-head comparison between SRS, (18)F-FDG and (18)F-FDOPA PET/CT in a patient with recurrent SDHC-related jugular paraganglioma.
    European journal of nuclear medicine and molecular imaging, 2012, Volume: 39, Issue:10

    Topics: Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Membrane Pr

2012
Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions.
    Clinical endocrinology, 2013, Volume: 79, Issue:2

    Topics: Abdominal Neoplasms; Adrenal Gland Neoplasms; Dihydroxyphenylalanine; False Negative Reactions; Head

2013
Biochemical and clinical manifestations of dopamine-producing paragangliomas: utility of plasma methoxytyramine.
    The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:4

    Topics: Adrenal Gland Neoplasms; Adult; Dihydroxyphenylalanine; Dopamine; Female; Humans; Male; Middle Aged;

2005
Fluorine-18 DOPA PET imaging of paraganglioma syndrome.
    Clinical nuclear medicine, 2006, Volume: 31, Issue:1

    Topics: Abdominal Neoplasms; Child; Dihydroxyphenylalanine; Head and Neck Neoplasms; Humans; Male; Paragangl

2006